Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARK7 | Q99497 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.71 |
| ▸ | ALDH3A1 | P30838 | 7/20 | 0.71 |
| ▸ | ALDH2 | P05091 | 3/20 | 0.71 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | CES1 | P23141 | 1/20 | 0.67 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.66 |
| ▸ | CA1 | P00915 | 3/20 | 0.64 |
| ▸ | CA2 | P00918 | 3/20 | 0.64 |
| ▸ | CA9 | Q16790 | 3/20 | 0.64 |
| ▸ | CA12 | O43570 | 2/20 | 0.64 |
| ▸ | CASP1 | P29466 | 1/20 | 0.63 |
| ▸ | CASP3 | P42574 | 1/20 | 0.63 |
| ▸ | CASP4 | P49662 | 1/20 | 0.63 |
| ▸ | CASP7 | P55210 | 1/20 | 0.63 |
| ▸ | CASP9 | P55211 | 1/20 | 0.63 |
| ▸ | CASP6 | P55212 | 1/20 | 0.63 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.63 |
| ▸ | NSD2 | O96028 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12930212 | 0.88 | ALDH1A1 (0.67) | PARK7ALDH1A1ALDH3A1ALDH2CHRM5 | |
| SCHEMBL4597660 | 0.87 | CHRM5 (0.73) | PARK7ALDH1A1ALDH3A1ALDH2CHRM5 | |
| SCHEMBL10369984 | 0.84 | CHRM5 (0.58) | PARK7ALDH1A1ALDH3A1ALDH2CHRM5 | |
| SCHEMBL9097463 | 0.83 | PARK7 (0.67) | PARK7ALDH1A1ALDH3A1ALDH2CHRM5 | |
| SCHEMBL16798714 | 0.83 | ALDH3A1 (1.00) | ALDH1A1ALDH3A1ALDH2CHRM1CES1 | |
| SCHEMBL10979016 | 0.83 | ALDH1A1 (0.69) | PARK7ALDH1A1ALDH3A1ALDH2CHRM5 | |
| SCHEMBL30937981 | 0.83 | CHRM5 (1.00) | PARK7ALDH1A1ALDH3A1ALDH2CHRM5 | |
| SCHEMBL28365954 | 0.82 | TRPA1 (0.59) | PARK7ALDH1A1ALDH3A1ALDH2CHRM5 | |
| SCHEMBL3021031 | 0.82 | CHRM5 (0.72) | PARK7ALDH1A1ALDH3A1CHRM5CA1 | |
| SCHEMBL13627936 | 0.82 | TRPA1 (0.62) | PARK7ALDH1A1ALDH3A1ALDH2CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118459390-B | 3-Hydroxy oxindole derivative containing Z-type 1, 4-dicarbonyl olefin, and preparation method and application thereof | SUN YAT-SEN UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| EP-4536642-A1 | HETEROCYCLIC COMPOUNDS AS PI3KA INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-118459390-A | 3-Hydroxy oxindole derivative containing Z-type 1, 4-dicarbonyl olefin, and preparation method and application thereof | 中山大学 | 2024-08-09 | — | — | CN | disclosed |
| WO-2023239846-A1 | HETEROCYCLIC COMPOUNDS AS PI3KΑ INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239846-A1 | HETEROCYCLIC COMPOUNDS AS PI3KΑ INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-112920191-B | Arylethynyl oxindole oxirane as well as preparation method and application thereof | 南宁师范大学 | 2022-03-25 | — | — | CN | disclosed |
| US-RE47731-E1 | Kinase inhibitors and method of treating cancer with same | UNIV HEALTH NETWORK (CA) | 2019-11-19 | — | — | US | disclosed |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2019-07-23 | — | — | US | disclosed |
| US-20180282306-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2018-10-04 | — | — | US | disclosed |
| US-10077255-B2 | Synthesis of chiral 2-(1H-indazol-6-yl)-spiro[cyclopropane-1,3′-indolin]-2′-ones | UNIVERSITY HEALTH NETWORK (CA) | 2018-09-18 | — | — | US | disclosed |
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORKS (CA) | 2012-06-14 | — | — | US | disclosed |
| EP-2417127-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | University Health Network (CA) | 2012-02-15 | — | — | EP | disclosed |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORKS (CA) | 2011-10-27 | — | — | US | disclosed |
| WO-2011123946-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011123947-A1 | SYNTHESIS OF CHIRAL 2-(1H-INDAZOL-6-YL)-SPIRO[CYCLOPROPANE-1,3'- INDOLIN]-2'-ONES | UNIVERSITY HEALTH NETWORK (CA) | 2011-10-13 | — | — | WO | disclosed |
| US-20110009379-A1 | INDOLINONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009379-A1 | INDOLINONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2261206-A1 | INDOLINONE COMPOUND | Astellas Pharma Inc. (JP) | 2010-12-15 | — | — | EP | disclosed |
| WO-2010115279-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2010-10-14 | — | — | WO | disclosed |
| WO-2009123080-A1 | INDOLINONE COMPOUND | アステラス製薬株式会社 (JP) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K5, MAP3K6, MAP3K1 | PARK7 3331/4885ALDH1A1 2633/4885ALDH3A1 2473/4885 |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | PARK7 3683/4885ALDH1A1 2389/4885ALDH3A1 2333/4885 |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | MAP3K6, MAP3K5, MAP3K19 | PARK7 3683/4885ALDH1A1 2389/4885ALDH3A1 2333/4885 |
| US-20110009379-A1 | INDOLINONE COMPOUND | TRPA1, TRPV1, TRPV6 | PARK7 516/4885ALDH1A1 1687/4885ALDH3A1 2467/4885 |
| US-10077255-B2 | Synthesis of chiral 2-(1H-indazol-6-yl)-spiro[cyclopropane-1,3′-indolin]-2′-ones | IDO1, IDO2, IMPA1 | PARK7 902/4885ALDH1A1 238/4885ALDH3A1 263/4885 |
| US-20180282306-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | PARK7 3683/4885ALDH1A1 2389/4885ALDH3A1 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.